Adjuvant Therapy

Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma

Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma

By

Researchers report on finding of a double-blind phase 3 study on the efficacy of adjuvant vemurafenib in patients with resected stage IIC to IIIB melanoma.

Adjuvant Gemcitabine Regimen Improves PFS in Upper Tract Urothelial Cancer

Adjuvant Gemcitabine Regimen Improves PFS in Upper Tract Urothelial Cancer

By

Investigators compared adjuvant gemcitabine plus cisplatin vs surveillance and subsequent chemotherapy if needed for patients who underwent nephron-ureterectomy for UTUC.

Adjuvant Therapy Duration a Continuous Discussion in HR+ Breast Cancer

Adjuvant Therapy Duration a Continuous Discussion in HR+ Breast Cancer

By

Choosing the optimal adjuvant therapy option for a patient with early-stage HR-positive breast cancer should be a continuous discussion with the patient, according to a presentation at SABCS 2017.

Adjuvant Endocrine Therapy Benefits Younger Women With ER+ Breast Cancer

Adjuvant Endocrine Therapy Benefits Younger Women With ER+ Breast Cancer

By

A comparison of adjuvant endocrine therapies showed one option provided greater reduction in disease recurrence among premenopausal women with ER+ breast cancer.

Gefitinib Adjuvant Therapy Prolonged Disease-Free Survival in EGFR-Mutant NSCLC

Gefitinib Adjuvant Therapy Prolonged Disease-Free Survival in EGFR-Mutant NSCLC

By

Results of this randomized, phase 3 study comparing oral gefitinib with IV vinorelbine plus cisplatin revealed the effect of these regimens on disease-free survival in patients with exon 19 deletion or exon Leu585Arg NSCLC.

Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC

Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC

By

Patients with stage III NSCLC have a poor median PFS of 8 months despite achieving a good response to the current standard of care of platinum-based double chemotherapy with concurrent radiotherapy.

Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma

Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma

By

Time to disease progression was significantly prolonged in patients with multiple myeloma who received lenalidomide therapy after ASCT.

Breast Conservation Improves Survival vs Mastectomy in Breast Cancer

Breast Conservation Improves Survival vs Mastectomy in Breast Cancer

By

Results of a recent study demonstrated overall survival was better among women who underwent breast-conserving surgery vs mastectomy. Furthermore, best overall survival was achieved with adjuvant radiotherapy in the former group and systemic therapy in the latter group.

Adjuvant Partial Breast Radiotherapy Noninferior in Preventing Relapse in Local Breast Cancer

Adjuvant Partial Breast Radiotherapy Noninferior in Preventing Relapse in Local Breast Cancer

By

Partial-breast and reduced-dose radiotherapy was found to be noninferior in preventing local relapse compared with whole-breast radiation therapy in patients with early stage breast cancer with a lower-than-average risk of relapse.

QOL, Adverse Effects Better With Capecitabine After Adjuvant Epirubicin for Breast Cancer

QOL, Adverse Effects Better With Capecitabine After Adjuvant Epirubicin for Breast Cancer

By

Women with breast cancer who received capecitabine after adjuvant epirubicin had better quality of life (QOL) compared with those who received CMF after adjuvant therapy.

Doxorubicin Efficacy Improved, Cardiotoxicity Reduced With Adjuvant Fidarest for Colon Cancer

Doxorubicin Efficacy Improved, Cardiotoxicity Reduced With Adjuvant Fidarest for Colon Cancer

By

The AR inhibitor fidarestat is effective as adjuvant therapy to enhance doxorubicin sensitivity of colorectal cancer cells and to reduce cardiotoxicity associated with the drug.

Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer

Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer

By

Adding a second HER2-blocker to standard care therapy after surgery for HER2-positive breast cancer may be modestly beneficial for some women.

Adjuvant + Neoadjuvant Pembrolizumab Safe in Patients Undergoing HNSCC Surgery

Adjuvant + Neoadjuvant Pembrolizumab Safe in Patients Undergoing HNSCC Surgery

By

Study also provides evidence supporting an anti-tumor effect associated with a single preoperative dose of pembrolizumab.

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

By

Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.

Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival

Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival

By

Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

By

Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.

Underuse, Misuse of Adjuvant Endocrine Therapy for Breast Cancer Has Decreased

Underuse, Misuse of Adjuvant Endocrine Therapy for Breast Cancer Has Decreased

By

Although significant variation in care persists, underuse and misuse of adjuvant endocrine therapy for breast cancer has decreased since 2004.

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

By

Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.

ASCO, ASTRO Issue Guideline Update for Postmastectomy RT

ASCO, ASTRO Issue Guideline Update for Postmastectomy RT

By

The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology have issued a joint consensus guideline update for the use of radiotherapy following mastectomy in patients with breast cancer.

Cognitive Impairment Common With Adjuvant Therapy in Older Patients With Early Stage Breast Cancer

Cognitive Impairment Common With Adjuvant Therapy in Older Patients With Early Stage Breast Cancer

By

Cognitive decline associated with adjuvant chemotherapy was more likely to occur in older patients, particularly those whose treatment included docetaxel.

Adjuvant Therapy Improves Survival in Stage II Colon Cancer, Study Confirms

By

A very large retrospective study of patients with stage II colon cancer found adjuvant therapy improves survival, regardless of treatment regimen, patient age, or high-risk pathologic risk features.

Adjuvant CRT Feasible for High-risk Endometrial Cancer

By

Adjuvant chemotherapy administered during and after radiotherapy is feasible for the treatment of patients with high-risk endometrial cancer despite an increased risk of toxicities compared with radiotherapy alone.

Adjuvant Chemotherapy Improves Overall Survival in Early Stage NSCLC

By

Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.

Adjuvant Chemotherapy Improves Survival in Stage IB NSCLC

Adjuvant Chemotherapy Improves Survival in Stage IB NSCLC

By

In patients with completely resected stage IB NSCLC, adjuvant chemotherapy is associated with improved survival regardless of tumor size.

NSCLC: Study Assesses Adjuvant Chemo Decision-making Role Preferences

NSCLC: Study Assesses Adjuvant Chemo Decision-making Role Preferences

By

Most patients with resected non-small cell lung cancer (NSCLC) preferred a collaborative role in decision-making about adjuvant chemotherapy.

Novel Procedure Improves Staging of Lymph Nodes in Patients With Breast Cancer

Novel Procedure Improves Staging of Lymph Nodes in Patients With Breast Cancer

By

The accuracy of axillary staging and of pathologic evaluation of clinically node-positive breast cancer is improved by a new procedure, reducing the need for a more invasive procedure with debilitating complications.

Breast Cancer Adjuvant Therapy Benefit Can Wax and Wane Over Time

By

Women are prescribed adjuvant therapies after breast cancer surgery to reduce the risk of cancer recurrence. The effects of these therapies have been assumed to remain constant over time, but a new study suggests the opposite is true.

Use of new systemic adjuvant therapy in gastrointestinal tumors increasing

Use of new systemic adjuvant therapy in gastrointestinal tumors increasing

By

Use of adjuvant systemic therapy for localized gastrointestinal stromal tumors has significantly increased over time and patients treated with the therapy have improved survival over surgery alone, according to study data.

Breast cancer tumor response to neoadjuvant chemotherapy (NAC) measured

By

Diffuse optical spectroscopic tomographic imaging (DOST) may be useful in predicting which patients will best respond to chemotherapy used to reduce breast cancer tumors before surgery, according to a new study.

Trastuzumab shows benefit years after treatment for HER2+ breast cancer

By

The addition of trastuzumab to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs